Dosing

In many people with von Willebrand disease, the activity of both von Willebrand factor (VWF) and factor VIII (FVIII) are reduced.1

For effective prevention and treatment of bleeds, the activity of both clotting factors needs to be restored. wilate® contains VWF and FVIII in a physiological 1:1 activity ratio to simultaneously restore the activity of both clotting factors, and facilitate simple and predictable dosing.2, 3

wilate® contains VWF and FVIII in a 1:1 ratio

Many people with von Willebrand disease also have low levels of FVIII, which also needs to be corrected in order to restore normal haemostasis1


wilate® contains VWF and FVIII in a 1:1 ratio*, similar to the ratio found in the blood of healthy individuals3

*Based on VWF and FVIII activity levels. FVIII, factor VIII; VWD, von Willebrand disease; VWF, von Willebrand factor.

The balanced physiological 1:1 ratio

of wilate® facilitates dosing and monitoring*

Because of the predictable decay of VWF and FVIII in wilate®, coagulation activity can be monitored using either VWF or FVIII levels


The ease of monitoring may help to ensure efficacy and tolerability of wilate® even after repeat dosing2

3_3@2x

*Based on von Willebrand factor and factor VIII activity levels. FVIII: factor VIII; VWF: von Willebrand factor.

The balanced physiological 1:1 ratio

of wilate® facilitates dosing and monitoring

3_4@2x

Parallel decay of VWF:RCo and FVIII:C


Simple dosing and monitoring using either VWF or FVIII levels

FVIII:C: FVIII clotting activity; FVIII: factor VIII; VWF:Ag: VWF antigen; VWF:RCo: von Willebrand Ristocetin Cofactor; VWF: von Willebrand factor.

wilate® reconstitution

Each wilate® package contains a vial of wilate® powder, a vial of sterile water*, a nextaro® transfer device and an infusion set.

The wilate® powder dissolves rapidly and the nextaro® transfer device allows quick and easy mixing to help save time during administration.

wilate® may be infused at a rate of 2–3 mL per minute.

*Includes 0.1% Polysorbate 80.

Dosing of wilate®

Recommended dosing for wilate®

*An initial dose of 50–80 IU/kg may be required, especially in patients with VWD type 3. †In some cases, such as in patients with gastrointestinal bleeds, higher doses may be necessary. FVIII:C: factor FVIII clotting activity for consistency; VWF:RCo: von Willebrand Ristocetin Cofactor.

Surgery
VWF:RCo target level: ≥60 IU/dL
FVIII:C target level: ≥40 IU/dL

An appropriate dose should be re-administered every 12-24 hours of treatment. The dose and duration of the treatment depend on the clinical status of the patient, the type and severity of bleeding, and both VWF:RCo and FVIII:C levels

On-demand treatment
20–50 IU/kg* to achieve adequate haemostasis

Prophylaxis
20–40 IU/kg
2 or 3 times per week†

wilate® range of vial sizes

wilate® is available in vials of 500 IU and 1000 IU. Each vial contains von Willebrand factor and factor VIII in a 1:1 ratio*.

Two dosing strengths of wilate

*Based on von Willebrand factor and factor VIII activity levels.

References

  1. Castaman G and James PD. Eur J Haematol 2019; 103:73-9.
  2. Kessler C et al. Thromb Haemost 2011; 106:279-88.
  3. Stadler M et al. Biologicals 2006; 34:281-8.
  4. wilate® SmPC, updated June 2021.